SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Lamarca Angela)
 

Search: WFRF:(Lamarca Angela) > Journal article > High-grade progress...

High-grade progression confers poor survival in pancreatic neuroendocrine tumors

Botling, Johan (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk och experimentell patologi
Lamarca, Angela (author)
Bajic, Duska (author)
Uppsala universitet,Endokrin tumörbiologi
show more...
Norlén, Olov (author)
Uppsala universitet,Endokrinkirurgi
Lönngren, Vincent, 1977- (author)
Uppsala universitet,Klinisk och experimentell patologi,Science for Life Laboratory, SciLifeLab
Kjaer, Josefin (author)
Uppsala universitet,Endokrinkirurgi
Eriksson, Barbro (author)
Uppsala universitet,Endokrin tumörbiologi
Welin, Staffan (author)
Uppsala universitet,Onkologisk endokrinologi
Hellman, Per (author)
Uppsala universitet,Endokrinkirurgi,Experimentell kirurgi
Rindi, Guido (author)
Skogseid, Britt (author)
Uppsala universitet,Endokrin tumörbiologi
Crona, Joakim (author)
Uppsala universitet,Endokrin tumörbiologi
show less...
 (creator_code:org_t)
2019-10-29
2020
English.
In: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 110:11-12, s. 891-898
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • INTRODUCTION: Little is known about how Pancreatic Neuroendocrine Tumors (PanNETs) evolve over time and if changes towards a more aggressive biology correlates with prognosis. The purpose of this study was to characterize changes PanNET differentiation and proliferation over time, and to correlate findings to overall survival (OS).PATIENTS AND METHODS: In this retrospective cohort study we screened 475 PanNET patients treated at Uppsala University Hospital, Sweden. Sporadic patients with baseline and follow-up tumor samples were included. Pathology reports and available tissue sections were re-evaluated with regard to tumor histopathology and Ki-67 index.RESULTS: Forty-six patients with 106 tumor samples (56 available for pathology re-evaluation) were included. Median Ki-67 index at diagnosis was 7% (range 1-38%), grade 1 n=8, grade 2 n=36, and grade 3 n=2. The median change in Ki-67 index (absolute value; follow-up - baseline) was +14% (range -11 to +80%). Increase in tumor grade occurred in 28 patients (63.6%), the majority from grade 1/2 to grade 3 (n=24, 54.5%). The patients with a high-grade progression had a median OS of 50.2 months compared to 115.1 months in patients without such progression (HR 3.89, 95% CI 1.91-7.94, P<0.001).CONCLUSIONS: A longitudinal increase in Ki-67 index and increase in tumor grade were observed in a majority of PanNETs included in this study. We propose that increase in Ki-67 index and high-grade progression should be investigated further as important biomarkers in PanNET.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)

Keyword

Pancreatic neuroendocrine tumor
Ki-67
Tumor grade
Proliferation
Prognosis
Evolution
Oncology
Onkologi
Patologi
Pathology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view